


PHARMACEUTICAL 2023

Kiniksa Pharmaceuticals Ltd. Rank 4 of 446







PHARMACEUTICAL 2023



Kiniksa Pharmaceuticals Ltd. Rank 4 of 446



The relative strengths and weaknesses of Kiniksa Pharmaceuticals Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kiniksa Pharmaceuticals Ltd. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 137% points. The greatest weakness of Kiniksa Pharmaceuticals Ltd. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 5.3% points.

The company's Economic Capital Ratio, given in the ranking table, is 331%, being 287% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	243,060
Cost of Goods Sold	0
Intangible Assets	18,250
Liabilities, Current	47,066
Liabilities, Non-Current	16,457
Other Assets	196,704
Other Compr. Net Income	110
Other Expenses	-125,371
Other Liabilities	0
Other Net Income	0
Other Revenues	221,433
Property and Equipment	1,658
Research and Development	65,490
Selling, General and Administrative Expense	97,951

Output Variable	Value in 1000 USD
Assets	459,672
Liabilities	63,523
Expenses	38,070
Revenues	221,433
Stockholders Equity	396,149
Net Income	183,363
Comprehensive Net Income	183,418
Economic Capital Ratio	331%